NkartaNKTX
About: Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Employees: 159
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
863% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $106K
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
6% more funds holding
Funds holding: 112 [Q2] → 119 (+7) [Q3]
0.2% more ownership
Funds ownership: 94.41% [Q2] → 94.61% (+0.2%) [Q3]
23% less capital invested
Capital invested by funds: $393M [Q2] → $302M (-$91.5M) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Mizuho Salim Syed 35% 1-year accuracy 7 / 20 met price target | 575%upside $16 | Outperform Maintained | 21 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target | 659%upside $18 | Buy Maintained | 11 Nov 2024 |
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target | 364%upside $11 | Buy Maintained | 8 Nov 2024 |
Financial journalist opinion
